GovChime
Notice ID: d56d9f3585c146eeb9ab9eea4174ee1aAward NoticeAwardedArchived

RNCP PORTFOLIO-WIDE DOSIMETRY VERIFICATION SERVICES

Awarded on July 30, 2026. The description is published on SAM.gov: Full description on SAM.gov.

Awarded tounder 75N98026C00051 (source: SAM.gov award notice)• $551.8K

Overview

Posted
August 6, 2026
Notice type
Award Notice
NAICS
541714: Research and Development in Biotechnology (except Nanobiotechnology)
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH NIAID
Place of performance
Rockville
Last updated
Oct 28, 2026
First published
Last updated on SAM.gov
Award date
Jul 30, 2026
Award amount (SAM.gov award notice)
$551.8K

Identifiers

Solicitation number
75N93023R0002
Notice ID
d56d9f3585c146eeb9ab9eea4174ee1a
Award number (PIID)
75N98026C00051

Description

No description in the SAM.gov data feed for this notice.

Full description on SAM.gov

Award Overview

Award Number

75N98026C00051

Award Amount (SAM.gov award notice)

$551.8K

Award Date

Jul 30, 2026

Awardee

Awardee UEI

Z9CRZKD42ZT1

Awardee CAGE Code

1B0S2

Original Solicitation

Notice ID: d56d9f3585c146eeb9ab9eea4174ee1a

Posted Date: Aug 6, 2026

Original Response Deadline: Not specified

More From This Vendor

Top 5 most recent

5
  • 75N93019C00055
    UNIVERSITY OF MARYLAND
    Department of Health and Human ServicesNAICS 541715
    $33.3MSigned Oct 21, 2026
  • 75N93019C00055
    UNIVERSITY OF MARYLAND
    Department of Health and Human ServicesNAICS 541715
    $33.3MSigned Sep 28, 2026
  • 75N93019C00055
    UNIVERSITY OF MARYLAND
    Department of Health and Human ServicesNAICS 541715
    $33.2MSigned Aug 11, 2026
  • 75N91020C00007
    UNIVERSITY OF MARYLAND, BALTIMORE
    Department of Health and Human ServicesNAICS 541715
    $7.6MSigned Jun 23, 2026
  • 75F40122P00382
    UNIVERSITY OF MARYLAND, BALTIMORE
    Department of Health and Human ServicesNAICS 541715
    $55.0KSigned Jun 5, 2026

Contacts

Contracting Officer

Primary Contact

Documents

No documents available.

Lifecycle

  1. 3
    Version 3SolicitationArchived

    RNCP PORTFOLIO-WIDE DOSIMETRY VERIFICATION SERVICES

    Notice 76c3814191d742dfa8b76709b2838a67 on SAM.gov

  2. 6
    Version 6Award NoticeArchivedCurrent

    Type changed from Solicitation to Award Notice

    RNCP PORTFOLIO-WIDE DOSIMETRY VERIFICATION SERVICES

    Notice d56d9f3585c146eeb9ab9eea4174ee1a on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
See attached Sources Sought Notice and attached Draft Statement of Work. SOURCES SOUGHT NOTICE Solicitation Number: 75N98027R00005 Title: Quantitative Analysis of Longitudinal MR Images Classification Code/Title: AN11 - Health R&D Services; Health Care Services; Basic Research NAICS Code/Title: 541714 Research and Development in Biotechnology (except Nanobiotechnology) Size Standard: 1,000 employees Description: This is a Research and Development (R & D) Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential R & D requirement. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Small businesses are encouraged to respond. Background: Since 1958, the Baltimore Longitudinal Study of Aging (BLSA) has been a major research program conducted by the National Institute on Aging (NIA). The BLSA is a multi-disciplinary study of physiologic and psychological aspects of normal aging in community-dwelling men and women. Active BLSA participants are volunteers who visit the Clinical Unit of the NIA-Intramural Research Program (IRP) in Baltimore, MD for testing every 1 to 4 years. Since 1994, the NIA has been conducting a longitudinal brain imaging study of older adults in the BLSA to characterize individual differences in longitudinal brain changes, to investigate the extent to which these brain changes underlie individual differences in cognitive aging, to identify brain changes that may be predictors of cognitive decline and Alzheimer’s disease, and to assess the impact of potential modulators of brain and cognitive aging. As of October, 2024, more than 4000 neuroimaging evaluations have been performed for BLSA participants. As part of this research program, it has also been necessary to develop and validate sophisticated tools for analysis of longitudinal neuroimaging data that can be applied in large-scale studies. Thus, this project has involved the development, validation, and refinement of novel image analysis tools and the application of these tools to longitudinal Magnetic Resonance (MR) imaging scans and Positron Emission Tomography (PET) measures of regional cerebral blood flow, amyloid and tau deposition in brain. More recently, these tools include advanced machine learning approaches using pattern analysis to classify clinical status and aging trajectories of individuals based on structural and functional brain images. The work of this requirement will continue to focus on the application of sophisticated tools and quantitative analysis of longitudinal MRI data acquired from BLSA participants. Thus, the proposed contract will apply methods developed in prior acquisitions, that allow continuity of research and provide longitudinal consistency of measures of global and regional brain volumes and ischemic lesion volumes, as well as functional MR data, including consistency with MR data acquired during earlier phases of this project (since 1994). This Contract will also require the application of sophisticated analytic approaches, including previously developed machine learning and pattern analysis methods, to allow classification of risk for cognitive impairment and likelihood of maintenance of cognitive resiience on an individual subject basis. Purpose and Objectives: The principal goal of this procurement is to provide quantification of MR imaging scans to provide measures of brain structure and function in BLSA participants, including heterogenous brain aging trajectories. Specifically, these data will allow NIA investigators to continue to address the following questions: What are the rates and regional distribution of changes in brain anatomy in non-demented men and women throughout adulthood? What is the frequency and progression of brain abnormalities in older adults and what is the clinical significance of these findings for cognitive aging? Against a background of age-related changes in brain structure, which changes predict cognitive impairment and Alzheimer’s disease, and conversely, what are the predictors of the maintenance of cognitive health or cognitive resilience? What factors modulate cognitive and brain aging and how do they impact brain-behavior associations? Project Requirements: See attached Draft Statement of Work. Anticipated Period of Performance: The anticipated period of performance is one year from date of award. Capability Statement/Information Sought: Companies that believe they possess the capabilities to provide the required products should submit documentation of their ability to meet each of the project requirements to the Contracting Officer. The capability statement must specifically address each of the project requirements separately. Additionally, the capability statement should include 1) the total number of employees, 2) the professional qualifications of personnel as it relates to the requirements outlined, 3) any contractor GSA Schedule contracts and/or other government-wide acquisition contracts (GWACs) by which all of the requirements may be met, if applicable, and 4) any other information considered relevant to this program. Capability statements must also include the Company Name, Unique Entity ID from SAM.gov, Physical Address, and Point of Contact Information. The response must include the respondents’ technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. Interested companies are required to identify their type of business, applicable North American Industry Classification System (NAICS) Code, and size standards in accordance with the Small Business Administration. The government requests that no proprietary or confidential business data be submitted in a response to this notice. However, responses that indicate the information therein is proprietary will be properly safeguarded for Government use only. Capability statements must include the name and telephone number of a point of contact having authority and knowledge to discuss responses with Government representatives. Capability statements in response to this market survey that do not provide sufficient information for evaluation will be considered non-responsive. When submitting this information, please reference the solicitation notice number. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2” x 11” paper size, with 1” top, bottom, left and right margins, and with single or double spacing. The information submitted must be in and outline format that addresses each of the elements of the project requirement and in the capability statement /information sought paragraphs stated herein. A cover page and an executive summary may be included but is not required. The response is limited to ten (10) page limit. The 10-page limit does not include the cover page, executive summary, or references, if requested. All responses to this notice must be submitted electronically to the Contract Specialist and Contracting Officer. Facsimile responses are NOT accepted. The response must be submitted to Sneha Singh, Contract Specialist at e-mail address sneha.singh@nih.gov. The response must be received on or before Monday, November 9, 2026, 9:00 AM, Eastern Time. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in betaSAM. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
72%
Market Research11/09/2026
Pre-solicitation Notice Information Introduction The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Microbiology and Infectious Diseases has a requirement to provide and develop animal models in order to advance our understanding of infectious diseases as well as advance the development of therapeutics and vaccines for infectious diseases. Description The National Institute of Allergy and Infectious Diseases (NIAID) supports and facilitates research that focuses on understanding, treating and, ultimately, preventing infectious, immunologic, and allergenic diseases. The NIAID Division of Microbiology and Infectious Diseases (DMID) supports and facilitates research to understand, control and prevent human disease caused by infectious agents. Basic, applied and translational research to develop and assess therapeutics, vaccines, and diagnostics is supported through research grants, cooperative agreements, and contracts. In turn, DMID further supports and facilitates research ongoing under these funding mechanisms and through other programs via an array of preclinical and clinical resources and services to support multiples stages of the product development pipeline. These resources and services include genomic and gene sequencing services, provision of high quality biological materials, biocontainment facilities, and pre-clinical and clinical translational research resources (https://www.niaid.nih.gov/research/resources). The current NIAID Preclinical Models of Infectious Diseases IDIQ contract program is one of DMID’s preclinical services resources and supports the development and refinement of animal models and animal replacement models of infectious diseases, models that subsequently are used to evaluate candidate medical countermeasures against these diseases. In addition, these contracts facilitate regulatory submissions, patents, and other intellectual property applications by extramural investigators who request evaluation of their products. This program serves the DMID mission of supporting investigator-initiated research by providing critical data needed to apply for grant or other funding. Finally, these contracts enable product developers and sponsors to make key go/no-go decisions for candidate therapeutics, vaccines, and diagnostics. In addition to meeting the needs of extramural researchers, this program provides crucial data to our DHHS agency partners. These data will facilitate the advancement of promising candidate medical countermeasures against priority biodefense and emerging infectious agents to approval or licensure, and, in some cases, eventual deposit in the Strategic National Stockpile. As background, in 2024, 40 institutions were awarded base contracts under the Preclinical Models of Infectious Diseases IDIQ contract program. This program was a re-competition of her Animal Models of Infectious Diseases IDIQ contract program, and its overarching goal was to provide capability in a broad range of animal and animal replacement models for use in evaluating promising candidate countermeasures (vaccines, therapeutics, diagnostics) against the broad range of infectious agents that are in the purview of DMID. The breadth of the existing contractor pool has enabled a rapid and effective response to emerging infectious diseases, such as COVID-19, and emergency preparedness priorities. Awarded contracts were divided into 4 model-specific pools: Task Area A – Small Animal Models of Infectious Diseases Task Area B – Non-Human Primate Models of Infectious Diseases Task Area C – Animal Replacement and Non-traditional Animal Models of Infectious Diseases Task Area D – Generation and Distribution of Specialized Reagents The Preclinical Models of Infectious Diseases program will continue to provide the capability and capacity to develop and employ animal and animal replacement models (e.g., organ-on-a-chip technology) of infectious diseases for screening and product evaluation and addresses a critical stage in this pipeline by bridging in vitro testing and eventual clinical evaluation, including as needed, studies conducted under the guidance of 21 CFR 58, “Good Laboratory Practices”. In addition, for candidate products that are unable to be assessed for clinical efficacy in phase II or III trials for ethical or practical reasons, contracts awarded under this solicitation will enable regulatory approval or licensure via the guidance of the FDA’s Animal Efficacy Rule (21 CFR 314.610 and 601.91). This anticipated “ramp-on” solicitation will award multiple IDIQ base contracts to successful offerors that propose a general approach to the requirements, allowing them to join the existing contractor pools. Successful offerors will qualify for the pool and be eligible to compete for future task order awards in the existing model-specific Task Areas: Task Area A – Small Animal Models of Infectious Diseases Task Area B – Non-Human Primate Models of Infectious Diseases Task Area C – Animal Replacement and Non-traditional Animal Models of Infectious Diseases Task Area D – Generation and Distribution of Specialized Reagents Offerors are encouraged to consider submission of proposals to one or more of the above Task Areas (depending upon capabilities). Contract awards are anticipated to the organizations whose proposals offer the best value to the Government. For the purposes of this solicitation, the following definitions apply: Animal replacement tissue technologies derived from human or animal tissue (in particular lung, liver, immune system, brain, skin/soft tissue or gastrointestinal tissues): Organoids Organs on chips Artificial complex cell systems Microphysiological systems Tissue technologies derived from animals, in particular, non-human primates (for the purposes of bridging data from in vivo models with clinical data) Evaluation: encompasses advanced testing after a product has been screened and demonstrated as efficacious in the same or lower animal models; activities include dose refinement, measurement of host response, pharmacokinetics (in infected animals), pharmacodynamics (in infected animals), and therapeutic efficacy or immune protection against challenge. Model development: a novel systematic effort to reproduce a clinical syndrome caused by an infectious agent in an animal species following challenge with the agent and includes median lethal and/or infectious dose determination, natural history of infection, and serial pathogenesis studies. Model refinement: a systematic effort to improve the performance of an existing animal model that reproduces a clinical syndrome caused by an infectious agent; to adapt an existing animal model that reproduces a clinical syndrome caused by one infectious agent to a different, but related, infectious agent; to adapt an existing animal model to optimize its ability to support product screening or evaluation following challenge with the infectious agent. Non-human primate models: new and old-world species, including but not limited to Macaca, spp. (cynomolgus, Rhesus, pig-tailed); Chlorocebus, spp. (African green monkeys, vervets); Aotus, spp.; Papio, spp.; Callithrix, spp. (marmosets) Non-traditional animal models including but not limited to: Domestic livestock: horses, cattle, goats, sheep, fowl Wildlife species: marmots, wild rodents, deer, bats Invertebrates: snails, parasitic nematodes, parasitic protozoa, insect vectors of human disease Aquatic: zebrafish HFIM Pathogens: infectious bacteria, viruses, parasites, fungi, toxins, and other agents such as prions that cause clinical syndromes in humans (surrogate human pathogen/animal combinations may be used for diseases where human pathogens cannot be studied in animal models) Products: agents for the prevention of infectious diseases such as vaccines or microbicides; therapeutics targeting the host or the pathogen, including conventional drugs, immunotherapeutics, and therapeutic vaccines; and diagnostics (Also referred to as candidate medical countermeasures or countermeasures.) Reagents: biochemical, genomic, molecular, cellular, and immunologic materials integral to research on pathogens, including the pathogenic agent or toxin itself requiring an in vivo model for production (e.g., hybridomas, monoclonal antibodies, otherwise unculturable organisms, live vectors) Screening: encompasses early-stage or first-in-animal testing for product effectiveness in animals; activities include rudimentary testing of product effectiveness after challenge, determination of maximum tolerated dose, and minimum effective dose. Small animal models: includes but is not limited to traditional laboratory rodent species (mice, rats, hamsters, gerbils (including jirds), guinea pigs), transgenic, humanized knock-out, and knock-in mouse strains, cotton rats, laboratory rabbit varieties, and laboratory ferrets The services encompass the following: Small animal models: development of new and refinement of existing models amenable for evaluating candidate countermeasures; evaluation of candidate countermeasures, including but not limited to, maximum tolerated dose, minimum effective dose, safety, efficacy, pharmacokinetics, pharmacodynamics Non-human primate models: development of new and refinement of existing models amenable for evaluating candidate countermeasures; evaluation of candidate countermeasures, including but not limited to, maximum tolerated dose, minimum effective dose, safety, efficacy, pharmacokinetics, pharmacodynamics Animal replacement models and non-traditional animal models: development of new and refinement of existing models amenable for evaluating candidate countermeasures; evaluation of candidate countermeasures, including but not limited to, maximum tolerated dose, minimum effective dose, safety, efficacy, pharmacokinetics, pharmacodynamics studies to bridge animal and animal replacement model Generation and Distribution of Specialized Reagents including but not limited to: Production of live life cycle stages for parasitic infections (e.g., eggs, pupae, larvae, adult stage parasites) Production of live vectors that support life cycle stages of parasitic infections (e.g., mosquitoes, ticks, fleas, black flies, sand flies, tsetse flies, reduviid bugs) Tissues required for isolation of otherwise unculturable infectious agents or toxins that can be distributed as reagents Production of monoclonal and polyclonal antibodies and hybridomas in mice Model species that are not listed with the individual Task Areas above, but are requested for development or demonstrated as necessary for testing medical countermeasures following award, will be taken under advisement by the Government, and task order requirements involving these model species may be developed on a case-by-case basis as long as they are determined to represent benefit to the Government. The services shall be directed at, but not be limited to, the following areas of emphasis: RNA viruses with the potential to cause pandemics from the following viral families: Bunyaviridae Coronaviridae Enteroviridae (in particular, EV-D68 and EV-71) Filoviridae Flaviviridae (in particular dengue and West Nile viruses) Paramyxoviridae (in particular Hendra and Nipah viruses) Togaviridae Antimicrobial resistant and multi-drug resistant infections, including Methicillin- Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus, Carbapenem-Resistant Enterobacteriaceae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Clostridium difficile Diseases caused by pathogens and toxins on the National Institute of Allergy and Infectious Diseases (NIAID) Emerging Infectious Diseases/Pathogens list: http://www.niaid.nih.gov/topics/biodefenserelated/biodefense/pages/cata.aspx ; in particular, influenza, viral hemorrhagic fevers (including arthropod-borne viruses), arthropod-borne encephalitis viruses, rabies, and Mycobacterium tuberculosis (including MDR and XDR strains), Bordetella pertussis, Group A Streptococcus; Fungal diseases, including invasive aspergillosis, candidiasis, coccidioidomycosis, cryptococcosis, mucormycosis , pneumocystis pneumonia; Non-Biodefense Bacteria, including Chlamydophila pneumonia, Haemophilus, spp., Legionella, spp, non-tuberculous Mycobacterial spp., Streptococcus pneumoniae, Non-Biodefense Viruses, including: adenoviruses Hepatitis B and C viruses, Herpesviruses (HSV 1 and 2, CMV, VZV, HHV-6/7), human metapneumovirus, respiratory syncytial virus, papillomaviruses, parainfluenza virus; Neglected tropical diseases, including: filariasis, leprosy, schistosomiasis, trachoma, trichomoniasis; and Sexually transmitted infections, including bacterial vaginosis, chlamydia, and gonorrhea The NIAID recognizes that a single organization or institution may not have the full spectrum of expertise or facilities required to perform all activities set forth in the Statement of Work. Contractors shall perform the work described in one or more Task Areas. Contractors may need to be supported to a certain extent by the expertise and resources of other organizations or persons through consortia agreements, partnerships, subcontracts, and/or consultants. However, contractors shall be responsible for ALL work performed and shall be responsible for project planning, initiation, implementation, management, and communication; evaluation, selection, and management of subcontractors; and for all deliverables specified in this contract and each awarded Task Order. Any responsible Offeror may submit a proposal which will be considered by the Agency. This RFP will be available electronically on/about December 2026 and may be accessed through sam.gov. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted. For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. The content of the disc and online proposals must be identical. Submission of proposals by facsimile or e-mail is not acceptable. For directions on using eCPS, go to the website https://ecps.niaid.nih.gov and then click on "How to Submit." To submit online using eCPS, offerors must have a valid NIH electronic Research Administration (eRA) Commons account, which provides authentication and serves as a vehicle for secure transmission of documents and communication with the NIAID. The eRA Commons registration process may take up to 4 weeks. For more information, please see https://www.era.nih.gov/register-accounts/register-in-era-commons.htm.”
71%
Pre-Solicitation12/07/2026
NOTICE OF A PROPOSED CONTRACT ACTION NON-COMPETITIVE Notice ID: 75N95022C00004 Contract Opportunity Type: Presolicitation Response Date: November 27, 2026, at 1:00 PM Eastern Time (15 days) Classification: No Small Business Set Aside Used Product Service Code: AN11 NAICS Code: 541715 Place of Performance: Blank Description PURSUANT TO RFO 5.101 — PRESOLICITATION NOTICE, THIS IS A NOTICE OF A PROPOSED CONTRACT ACTION. THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE MODIFICATION UNDER CONTRACT NO. 75N95022C00004 WITH VIRGINIA COMMONWEALTH UNIVERSITY. THIS IS NOT A SOLICITATION OR A REQUEST FOR COMPETITIVE PROPOSALS. The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), through the Addiction Treatment Discovery Program (ATDP) within NIDA’s Division of Therapeutics and Medical Consequences (DTMC), intends to modify Single Award Contract No. 75N95022C00004, “Preclinical Medications Discovery and Abuse Liability Testing for NIDA,” to extend the period of performance by 12-months through February 21, 2027. All other terms and conditions remain unchanged. This modification will allow for the continuation of ongoing research conducted under the Preclinical Medications Discovery and Abuse Liability Testing program for NIDA and prevent any delays or disruption to the development of therapeutics essential for ongoing and upcoming pre-clinical and clinical trials while a new contract is properly planned and competed. REGULATORY AUTHORITY The resultant modification will include all applicable provisions and clauses of the Revolutionary FAR Overhaul (RFO) Initiative, in accordance with Executive Order 14275 and OMB Memorandum M-25-26. STATUTORY AUTHORITY This modification is conducted under the authority of 41 U.S.C. 3304(a)(1) and in accordance with RFO 6.103-1 Only one responsible source and no other supplies or services will satisfy agency requirements. CLOSING STATEMENT THIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. However, interested parties may identify their interest and capability to respond to this notice. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. All responsible sources may submit a capability statement, proposal, or quotation which shall be considered by the agency. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All responses must be received by the closing date and time of this announcement and must reference the Project Title, “Preclinical Medications Discovery and Abuse Liability Testing for NIDA.” Responses must be submitted electronically to Shayna Simpson, Contracting Officer, at shayna.simpson@nih.gov. Mailed and faxed responses will not be accepted. PRIMARY POINT OF CONTACT: Shayna Simpson Email: shayna.simpson@nih.gov Phone: 301-402-9712
66%
Pre-Solicitation11/27/2026
This is a SMALL BUSINESS SOURCES SOUGHT NOTICE. This is NOT a solicitation for proposals, proposal of abstracts or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses (e.g., 8(a), Veteran-owned small businesses, service-disabled Veteran-owned small businesses, HUBZone small businesses, small disadvantaged businesses, and women-owned small businesses); (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition; and (4) whether commercials sources and services are available in the marketplace. Your response to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code 541715 should not submit a response to this notice. This notice is issued to help determine the appropriate acquisition method including small business socioeconomic set aside possibilities and to determine the availability of commercial or non-commercial companies technically capable of meeting the Government's potential requirement. It is not construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Furthermore, it should be noted that any future solicitations that may be issued as a result of this notice, or in response to this requirement, may be issued using a different solicitation number from the one identified above. The National Institute on Drug Abuse (NIDA) Division of Therapeutics and Medical Consequences (DTMC) and National Institutes of Health (NIH) is seeking Capability Statements from Small Business organizations with the demonstrated capability of providing service to support NIDA DTMC with the synthesis and distribution of drugs of abuse and related compounds. BACKGROUND AND OBJECTIVES: The National Institute on Drug Abuse (NIDA) is seeking capability statements from small businesses with the capability to synthesize and distribute drugs of abuse and related compounds. The NIDA Drug Supply Program has played an important role in promoting and supporting the substance use research by providing a wide variety of authentic, pure, controlled and uncontrolled drugs and other chemical compounds (both unlabeled and labeled with deuterium, tritium, carbon -14, and iodine-125 isotopes) to the drug abuse research community for basic research. To continue to supply authentic and pure drugs and research chemicals, NIDA maintains the drug supply inventory, periodically check chemical purity and supply to research investigators according to the NIDA drug supply guidelines. Specifically, NIDA plans to continue to: (1) produce, acquire, synthesize and maintain several radio and deuterium labeled and unlabeled drugs of abuse and other chemical substances in its drug supply inventory and distribute them to research investigators upon approval; (2) analyze, test, establish, and maintain the purity of drugs of abuse, and other chemical compounds in the NIDA drug supply inventory and produce updated chemical data sheets; (3) to replenish existing drug supply inventory with depleted drugs and research compounds with the synthesis or acquisition of depleted drug/chemical substances routinely; (4) to identify, acquire, and update the drug supply inventory with newly discovered chemical compounds useful for drug abuse research; (5) to use, maintain, and update the NIDA drug supply data base, known as Drug Inventory Supply Control System (DISCS); and (6) accept and process request packages from researchers; (7) Provide secure storage for all compounds and safe shipment of approved drugs/compounds to research investigators. Capable vendors must demonstrate the capability to receive the current inventory of hundreds of DEA controlled and uncontrolled drugs, other chemical compounds including peptides (opioid and related neuropeptides) in several kilogram quantities for immediate storage. Many of these compounds will require refrigeration. Some substances are in solution form and therefore require appropriate and secure storage to meet DEA requirements. Chemical compounds to be synthesized shall include new drugs, drug metabolites and other compounds as directed by NIDA. Specific compounds may include but not be limited to unlabeled compounds as well as compounds labeled with tritium, 125I, 14C, and deuterium and 13C. Representative classes of compounds shall include cannabinoids, hallucinogens, narcotics and antagonists, stimulants, depressants, peptides (opioid and related neuropeptides). All chemical compounds must be stored under optimum shelf‑life conditions and their purity maintained at not less than 95%. Re-purification must be carried out if chemical or radiochemical deterioration occurs. MANDATORY REQUIREMENTS: To handle controlled substances under the Controlled Substances Act of 1970, it is mandatory that the successful capable vendors possess a DEA Research Registration for Schedules II to V and demonstrate the capability to obtain a DEA registration for Schedule I controlled substances. INSTRUCTIONS: Based on preliminary market research, the Government has determined that the requirements described herein do not meet the definition of a commercial product or commercial service as defined in RFO 2.101, and therefore, RFO Part 12 procedures are not applicable to this requirement. However, if a capable vendor believes that these services or products qualify as commercial under FAR 2.101, the vendor may submit a written justification for the Contracting Officer's consideration. Such submissions must be provided to the Contracting Officer no later than November 20, 2026 at 1:00 PM EST. Respondents must provide clear and convincing documentation of their capability and experience with providing the personnel and services as specified in the tasks above. Also, information must be provided in sufficient details of the respondents’ (a) staff expertise, including their availability, experience, formal and other training; (b) current capability to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and other management capability; and (e) examples of prior completed Government contracts, references, and other related information. Each capability statement must include the respondent’s UEI number, organization name, and address. Each response should include the technical and administrative points of contact with, names, titles, addresses, telephone numbers, and e-mail addresses. The capability statement should clearly identify the size and type of business (e.g., 8(a), HubZone, Non-Profit, Other Than Small Business, etc.), pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2” x 11” paper size, with 1” top, bottom, left and right margins, and with single or double spacing. The information submitted must be in an outline format that addresses each of the elements of the project requirement and in the capability statement paragraphs stated herein. A cover page and an executive summary may be included but is not required. The response is limited to ten (10) pages. The 10-page limit does not include the cover page, executive summary, resumes, or references, if requested. Any business concerns that believe they possess the capability necessary to successfully undertake the work described above must SUBMIT CAPABILITY STATEMENTS ELECTRONICALLY to the Contract Specialist, Shaun Rostad at Shaun.Rostad@nih.gov, NO LATER THAN 1:00 p.m. EST on November 20, 2026. The Subject line for the submission should include this Sources Sought Number, SAM.gov Unique Entity Identifier (UEI) and organization name. NIDA will not accept paper or faxed capability statements. THIS NOTICE IS NOT A REQUEST FOR PROPOSALS. This notice is for information and planning purposes only and does not commit the Government to any contractual agreement. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in SAM.gov. However, responses to this notice will not be considered adequate responses to a solicitation. CONFIDENTIALITY. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
63%
Market Research11/20/2026
This is a SOURCES SOUGHT NOTICE. This is NOT a solicitation for proposals, proposal of abstracts or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified business sources; (2) whether they are small businesses (e.g., 8(a), Veteran-owned small businesses, service-disabled Veteran-owned small businesses, HUBZone small businesses, small disadvantaged businesses, and women-owned small businesses); (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition; and (4) whether commercials sources and services are available in the marketplace. Your response to the information requested will assist the Government in determining the appropriate acquisition method. This notice is issued to help determine the appropriate acquisition method to determine the availability of commercial or non-commercial companies technically capable of meeting the Government's potential requirement. It is not construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Furthermore, it should be noted that any future solicitations that may be issued as a result of this notice, or in response to this requirement, may be issued using a different solicitation number from the one identified above. The National Institute on Drug Abuse (NIDA) Division of Therapeutics and Medical Consequences (DTMC) and National Institutes of Health (NIH) is seeking Capability Statements from business organizations with the demonstrated capability of providing service to support NIDA DTMC with the synthesis and distribution of drugs of abuse and related compounds. BACKGROUND AND OBJECTIVES: The National Institute on Drug Abuse (NIDA) is seeking capability statements from businesses with the capability to synthesize and distribute drugs of abuse and related compounds. The NIDA Drug Supply Program has played an important role in promoting and supporting the substance use research by providing a wide variety of authentic, pure, controlled and uncontrolled drugs and other chemical compounds (both unlabeled and labeled with deuterium, tritium, carbon -14, and iodine-125 isotopes) to the drug abuse research community for basic research. To continue to supply authentic and pure drugs and research chemicals, NIDA maintains the drug supply inventory, periodically check chemical purity and supply to research investigators according to the NIDA drug supply guidelines. Specifically, NIDA plans to continue to: (1) produce, acquire, synthesize and maintain several radio and deuterium labeled and unlabeled drugs of abuse and other chemical substances in its drug supply inventory and distribute them to research investigators upon approval; (2) analyze, test, establish, and maintain the purity of drugs of abuse, and other chemical compounds in the NIDA drug supply inventory and produce updated chemical data sheets; (3) to replenish existing drug supply inventory with depleted drugs and research compounds with the synthesis or acquisition of depleted drug/chemical substances routinely; (4) to identify, acquire, and update the drug supply inventory with newly discovered chemical compounds useful for drug abuse research; (5) to use, maintain, and update the NIDA drug supply data base, known as Drug Inventory Supply Control System (DISCS); and (6) accept and process request packages from researchers; (7) Provide secure storage for all compounds and safe shipment of approved drugs/compounds to research investigators. Capable vendors must demonstrate the capability to receive the current inventory of hundreds of DEA controlled and uncontrolled drugs, other chemical compounds including peptides (opioid and related neuropeptides) in several kilogram quantities for immediate storage. Many of these compounds will require refrigeration. Some substances are in solution form and therefore require appropriate and secure storage to meet DEA requirements. Chemical compounds to be synthesized shall include new drugs, drug metabolites and other compounds as directed by NIDA. Specific compounds may include but not be limited to unlabeled compounds as well as compounds labeled with tritium, 125I, 14C, and deuterium and 13C. Representative classes of compounds shall include cannabinoids, hallucinogens, narcotics and antagonists, stimulants, depressants, peptides (opioid and related neuropeptides). All chemical compounds must be stored under optimum shelf‑life conditions and their purity maintained at not less than 95%. Re-purification must be carried out if chemical or radiochemical deterioration occurs. MANDATORY REQUIREMENTS: To handle controlled substances under the Controlled Substances Act of 1970, it is mandatory that the successful capable vendors possess a DEA Research Registration for Schedules II to V and demonstrate the capability to obtain a DEA registration for Schedule I controlled substances. INSTRUCTIONS: Based on preliminary market research, the Government has determined that the requirements described herein do not meet the definition of a commercial product or commercial service as defined in RFO 2.101, and therefore, RFO Part 12 procedures are not applicable to this requirement. However, if a capable vendor believes that these services or products qualify as commercial under FAR 2.101, the vendor may submit a written justification for the Contracting Officer's consideration. Such submissions must be provided to the Contracting Officer no later than November 20, 2026 at 1:00 PM EST. Respondents must provide clear and convincing documentation of their capability and experience with providing the personnel and services as specified in the tasks above. Also, information must be provided in sufficient details of the respondents’ (a) staff expertise, including their availability, experience, formal and other training; (b) current capability to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and other management capability; and (e) examples of prior completed Government contracts, references, and other related information. Each capability statement must include the respondent’s UEI number, organization name, and address. Each response should include the technical and administrative points of contact with, names, titles, addresses, telephone numbers, and e-mail addresses. The capability statement should clearly identify the size and type of business (e.g., 8(a), HubZone, Non-Profit, Other Than Small Business, etc.), pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2” x 11” paper size, with 1” top, bottom, left and right margins, and with single or double spacing. The information submitted must be in an outline format that addresses each of the elements of the project requirement and in the capability statement paragraphs stated herein. A cover page and an executive summary may be included but is not required. The response is limited to ten (10) pages. The 10-page limit does not include the cover page, executive summary, resumes, or references, if requested. Any business concerns that believe they possess the capability necessary to successfully undertake the work described above must SUBMIT CAPABILITY STATEMENTS ELECTRONICALLY to the Contract Specialist, Shaun Rostad at Shaun.Rostad@nih.gov, NO LATER THAN 1:00 p.m. EST on November 20, 2026. The Subject line for the submission should include this Sources Sought Number, SAM.gov Unique Entity Identifier (UEI) and organization name. NIDA will not accept paper or faxed capability statements. THIS NOTICE IS NOT A REQUEST FOR PROPOSALS. This notice is for information and planning purposes only and does not commit the Government to any contractual agreement. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in SAM.gov. However, responses to this notice will not be considered adequate responses to a solicitation. CONFIDENTIALITY. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
63%
Market Research11/20/2026

Additional Details

Solicitation Number

75N93023R0002

Archive Date

Aug 14, 2026

Office Address

BETHESDA, MD, 20892